Statement from FDA on continuing efforts to maintain its strong oversight of generic drugs
date:Feb 25, 2019
rts of negative patient side effects or other concerns suggest a problem with a drug, the FDA investigates and, when appropriate, may require changes in how a medicine (both brand-name and generic versions) is used or manufactured.

FACT: We closely analyze reams of data to ensure the quality and safety of manufacturing throughout a products lifecycle

The FDA monitors many sources of data to ensure the safety and quality of generic manufacturing. One of the fundamental elements of overseeing th

06/18 00:42